‘We’ll Be First With Off-The-Shelf CAR-T,’ Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics
Aiming To Help Patients Who Fail Auto CAR-Ts
Executive Summary
As it and its competitors have failed on the first test of durability with their allogeneic CAR-T candidates, Precision Biosciences is looking to cross the line in a sub-group of responders – as well as prove the value of its gene-editing platform.
You may also be interested in...
Precision Picks New CEO To Tackle Gene Editing’s Commercial Challenges
Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.
Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid
Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.